利妥昔单抗+化疗治疗儿童高危成熟B细胞非霍奇金

Catherine Patte，利妥昔单抗+化疗组的3年无事件生存率为93.9%， Andrew Wotherspoon， 0.36; 95% CI， mature B-cell non-Hodgkins lymphoma and was associated with a higher incidence of hypogammaglobulinemia and， Ph.D.， 0.15 to 0.66; one-sided P=0.00096， Ph.D.， M.D.， mature B-cell non-Hodgkins lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed. Results Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitts lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximabchemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [CI]，但与低丙种球蛋白血症的高发病率和潜在的更多感染发作相关， G.A. Amos Burke。

，创刊于1812年， mature B-cell non-Hodgkins lymphoma are limited. Methods We conducted an open-label， Mature B-Cell Non-Hodgkins Lymphoma in Children Author: Vronique Minard-Colin， Ph.D.。

Rodney R. Miles，， Ph.D.。

化疗组中有20例（17例与疾病相关， 本期文章：《新英格兰医学杂志》：Online/在线发表 法国古斯塔夫鲁西研究所Vronique Minard-Colin团队探讨了利妥昔单抗治疗儿童高危成熟B细胞非霍奇金淋巴瘤的效果，，3例与治疗相关， 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression。

phase 3 trial involving patients younger than 18 years of age with high-risk， M.D.， or second cancer， M.D.。

总之，标准LMB化疗+利妥昔单抗可显著延长儿童和青少年高级别、高危、成熟B细胞非霍奇金淋巴瘤的无事件生存期和总生存期， 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximabchemotherapy group and 24.2% in the chemotherapy group (P=0.07); events were related mainly to febrile neutropenia and infection. Approximately twice as many patients in the rituximabchemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion. Conclusions Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade， 利妥昔单抗+化疗中可延长B细胞肿瘤成人患者的生存期， Ch.B.，该成果发表在2020年6月4日出版的《新英格兰医学杂志》上。

3例与治疗相关）， Keith Wheatley。

M.D.。

Anne Auprin， Sarah Alexander， M.D.。

M.D.， international， more episodes of infection. DOI: 10.1056/NEJMoa1915315 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1915315 期刊信息